【摘要】 目的 观察替雷利珠单抗联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法 采用电脑随机分组法将2020年1月—2024年6月福建医科大学附属龙岩第一医院收治NSCLC患者80例分为2组，传统化疗组(n=40)给予白蛋白紫杉醇+顺铂化疗，免疫治疗联合组(n=40)在传统化疗组基础上给予替雷利珠单抗治疗，21 d为1个化疗周期，共治疗3个周期。比较2组近期疗效，治疗前后肿瘤标志物、肺癌治疗功能评价量表(FACT-L)评分及不良反应。结果 免疫治疗联合组疾病控制率为92.50%,高于传统化疗组的70.00%(χ~2=6.646,P=0.010)。治疗3个周期后，2组癌胚抗原、糖类抗原125、神经元特异性烯醇化酶、细胞角蛋白19片段抗原21-1水平降低，FACT-L各维度评分升高，且免疫治疗联合组低/高于传统化疗组(P<0.01)。免疫治疗联合组不良反应总发生率为15.00%,低于传统化疗组的40.00%(χ~2=6.270,P=0.012)。结论 替雷利珠单抗联合化疗治疗晚期NSCLC效果较好，有助于降低肿瘤标志物水平，提升患者生活质量，安全性高。更多还原

【Abstract】 Objective To observe the clinical effect of tislelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Eighty NSCLC patients admitted to Longyan First Hospital Affiliated to Fujian Medical University from January 2020 to June 2024 were divided into two groups by computer random grouping method. The traditional chemotherapy group(n=40) was given albumin paclitaxel + cisplatin chemotherapy, and the immunotherapy combination group(n=40) was given tislelizumab treatment on the basis of the traditional chemotherapy group. twenty-one days was one chemotherapy cycle. A total of three cycles of treatment were provided. The short-term efficacy, tumor markers, FACT-L scores before and after treatment, and adverse reactions were compared between two groups. Results The diseasecontrol rate of the immunotherapy combination group was 92.50%, which was higher than 70.00% of the traditional chemotherapy group(χ~2=6.646, P=0.010). After three cycles of treatment, the levels of CEA, CA125, NSE and CYFRA21-1 in both groups decreased, the scores of each dimension of FACT-L increased, and the immunotherapy combination group were lower/higher than the traditional chemotherapy group(P< 0.01). The total incidence of adverse reactions in the immunotherapy combination group was 15.00%, which was lower than 40.00% in the traditional chemotherapy group(χ~2=6.270, P=0.012).Conclusion Tislelizumab combined with chemotherapy has a better effect in the treatment of advanced NSCLC. It helps to reduce the levels of tumor markers, improve the quality of life of patients, and has high safety.更多还原